阿达木单抗临床试验中炎症性肠病不良事件发生率低:九种疾病汇总分析
该分析汇总75项阿达木单抗临床试验,覆盖类风湿关节炎、脊柱关节炎、银屑病关节炎等九种非IBD适应症,共24,114例患者、36,508患者年暴露。总体IBD不良事件发生率为0.1/100患者年(95%CI 0.1-0.2),不同疾病间从无事件到外周SpA的0.8/100患者年不等,所有事件均发生于成人。
要点
- 阿达木单抗治疗非IBD适应症时IBD不良事件总体发生率低(0.1/100患者年)。
- 外周SpA的IBD不良事件发生率最高(0.8/100患者年),银屑病关节炎、葡萄膜炎及儿科试验无事件。
- 安慰剂对照期间,阿达木单抗组与安慰剂组IBD发生率均为0.1/100患者年。
核心结论
- 在九种非IBD疾病中,阿达木单抗临床试验的IBD不良事件发生率总体较低,包括中轴型脊柱关节炎;所有事件均发生在成人患者。
研究设计与样本
- 汇总分析75项阿达木单抗临床试验,涵盖类风湿关节炎、多关节型幼年特发性关节炎、儿童附着点炎相关关节炎、葡萄膜炎、化脓性汗腺炎、成人及儿童银屑病、银屑病关节炎、非银屑病性外周脊柱关节炎、中轴型脊柱关节炎(含非放射学中轴型)和强直性脊柱炎。
- 共纳入24,114例患者,代表36,508患者年的阿达木单抗暴露。
- IBD不良事件搜索词包括IBD、溃疡性结肠炎、克罗恩病和溃疡性直肠炎,事件定义为新发或加重/ flare。
主要发现
- 阿达木单抗治疗患者总体IBD不良事件发生率为0.1/100患者年(95%CI 0.1-0.2),共41例事件。
- 各疾病发生率从无事件(银屑病关节炎、葡萄膜炎和儿科试验)到外周SpA的0.8/100患者年(95%CI 0.2-2.2)不等。
- 中轴型脊柱关节炎的IBD发生率为0.6/100患者年(95%CI 0.4-1.0)。
- 安慰剂对照试验中,阿达木单抗组总体IBD发生率为0.1/100患者年(95%CI 0.0-0.3;6,781例患者中3例事件,2,752患者年暴露),安慰剂组为0.1/100患者年(95%CI 0.0-0.4;3,493例患者中1例事件,1,246患者年暴露)。
- 中轴型脊柱关节炎中,阿达木单抗组IBD发生率为0.5/100患者年(95%CI 0.1-1.4),安慰剂组为0.6/100患者年(95%CI 0.0-3.1)。
临床怎么用
- 对于接受阿达木单抗治疗的非IBD适应症患者,IBD不良事件风险总体较低,但外周SpA和中轴型SpA患者风险相对较高,临床仍需保持警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adalimumab is approved for treatment of Crohn's disease and ulcerative colitis. Thus, we postulated that exacerbation or new-onset of inflammatory bowel disease (IBD) would be rare events in patients treated with adalimumab for non-IBD indications. The objective was to evaluate the incidence of IBD adverse events (AEs) across adalimumab trials. METHODS: IBD AE rates in 75 adalimumab clinical trials in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, pediatric enthesitis-related arthritis, uveitis, hidradenitis suppurativa, adult and pediatric psoriasis, psoriatic arthritis, nonpsoriatic arthritis peripheral spondyloarthritis (SpA), axial SpA, including nonradiographic axial SpA, and ankylosing spondylitis, were analyzed. Search terms for IBD AEs (new onset or worsening/flare) included IBD, ulcerative colitis, Crohn's disease, and ulcerative proctitis. RESULTS: This analysis included 24,114 patients, representing 36,508 patient-years of adalimumab exposure. The overall rate of IBD AEs in adalimumab-treated patients was 0.1 (95% confidence interval [95% CI] 0.1-0.2)/100 patient-years (41 events), ranging from no events (psoriatic arthritis, uveitis, and pediatric trials) to 0.8 (95% CI 0.2-2.2)/100 patient-years in peripheral SpA. The rate of IBD in axial SpA was 0.6 (95% CI 0.4-1.0)/100 patient-years. During placebo-controlled trials, the overall IBD rate was 0.1 (95% CI 0.0-0.3)/100 patient-years for adalimumab groups (3 events in 6,781 patients; 2,752 patient-years of exposure) and 0.1 (95% CI 0.0-0.4)/100 patient-years for placebo groups (1 event in 3,493 patients; 1,246 patient-years of exposure). IBD rates in axial SpA were 0.5 (95% CI 0.1-1.4)/100 patient-years for adalimumab and 0.6 (95% CI 0.0-3.1)/100 patient-years for placebo. CONCLUSION: The rates of IBD AEs in adalimumab clinical trials were generally low across the evaluated diseases, including axial SpA; all events occurred in adult patients.
引用
- Elewaut D, Braun J, Anderson JK, et al. Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. Arthritis Care Res (Hoboken). 2021. PMID: 32100944. doi:10.1002/acr.24175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。